Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559326 | 0.95 | CTSS (0.59) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL3066637 | 0.95 | CTSS (0.59) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL29551986 | 0.95 | CTSS (0.59) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL22730085 | 0.95 | CTSS (0.59) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13090480 | 0.88 | CTSS (0.60) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL16588660 | 0.88 | CTSS (0.68) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL3063879 | 0.87 | CTSS (0.42) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL3063876 | 0.87 | CTSS (0.42) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13090648 | 0.87 | CTSS (0.42) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL22484282 | 0.86 | CTSS (0.52) | CTSSCTSBADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-03 | — | — | US | disclosed |
| US-11660288-B2 | Drug-controlled systems and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | SRRT, BPTF, MYCBP | CTSS 3754/4885CTSB 4535/4885ADRB3 4589/4885 |
| US-11660288-B2 | Drug-controlled systems and uses thereof | ATF4, MRPL21, SARS1 | CTSS 1489/4885CTSB 3062/4885ADRB3 1925/4885 |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | ATF4, MRPL21, TMPRSS2 | CTSS 1043/4885CTSB 2542/4885ADRB3 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.